ArticleInternational journal of clinical and experimental medicine2008
Biomarkers for type 1 diabetes.
Article in International journal of clinical and experimental medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Environmental determinants of islet autoimmunity (ENDIA): a pregnancy to early life cohort study in children at-risk of type 1 diabetes.BMC pediatrics · 2013Trial
- Dysfunction of PTEN-Associated MicroRNA Regulation: Exploring Potential Pathological Links in Type 1 Diabetes Mellitus.Medicina (Kaunas, Lithuania) · 2024Article
- Global miRNA expression reveals novel nuclear and mitochondrial interactions in Type 1 diabetes mellitus.Frontiers in endocrinology · 2022Article
- Immune cell trafficking to the islets during type 1 diabetes.Clinical and experimental immunology · 2019Review
- Serum biomarkers for diagnosis and prediction of type 1 diabetes.Translational research : the journal of laboratory and clinical medicine · 2018Review
- Proteomic analysis to identify candidate biomarkers associated with type 1 diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Article
- MicroRNA expression profiles and type 1 diabetes mellitus: systematic review and bioinformatic analysis.Endocrine connections · 2017Article
- Large-Scale Discovery and Validation Studies Demonstrate Significant Reductions in Circulating Levels of IL8, IL-1Ra, MCP-1, and MIP-1β in Patients With Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2015Article
- Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes.Frontiers in immunology · 2015Review
- Luminex and other multiplex high throughput technologies for the identification of, and host response to, environmental triggers of type 1 diabetes.BioMed research international · 2015Review
- Diagnostic accuracy of interferon gamma-induced protein 10 for tuberculosis: a meta-analysis.International journal of clinical and experimental medicine · 2014Article
- Circulating microRNAs as novel biomarkers for diabetes mellitus.Nature reviews. Endocrinology · 2013Review
- Serum adiponectin helps to differentiate type 1 and type 2 diabetes among young Asian Indians.Diabetes technology & therapeutics · 2013Article
- Sardinian Type 1 diabetes patients, Transthyretin and Mycobacterium avium subspecies paratuberculosis infection.Gut pathogens · 2012Article
- Novel biomarkers in type 1 diabetes.The review of diabetic studies : RDS · 2012Review
- From biomarkers to a clue of biology: a computation-aided perspective of immune gene expression profiles in human type 1 diabetes.Frontiers in immunology · 2012Article
- Development of a quantitative methylation-specific polymerase chain reaction method for monitoring beta cell death in type 1 diabetes.PloS one · 2012Article
- Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays.Molecular & cellular proteomics : MCP · 2011Article
- Proteomic technologies for the discovery of type 1 diabetes biomarkers.Journal of diabetes science and technology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Type 1 diabetes (T1D) is an autoimmune disorder characterized by the immune destruction of the insulin producing beta cells of the pancreatic islets. Autoimmunity towards pancreatic antigens results from complex interactions between multiple genes, environmental factors and the immune system. The autoimmune process may occur many years before the onset of clinical diabetes and this long asymptomatic period provides excellent opportunities for the prediction and prevention of the disease. Research in past four decades has identified a number of risk factors including susceptibility genes, gene and protein expression changes, cellular changes as well as environmental triggers, which may serve as excellent biomarkers for risk assessment. Furthermore, demographic and clinical parameters such as age and family history of diabetes and other autoimmune diseases are also important for risk assessment. Despite the identification of multiple useful biomarkers, the existing tests for T1D prediction are still imperfect and earlier biomarkers are also urgently needed. Because of the insufficient predictive power of individual risk factors, future biomarkers with better predictive power will most likely take advantage of the combinatorial power of multiple biomarkers of different nature and the integration of various biomarkers and demographic/clinical information will be the key to success.
Indexed as
Identifiers
19079665PMC2596319W1823860522What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.